Plasmodium falciparum cGMP-Dependent Protein Kinase – A Novel Chemotherapeutic Target
Abstract
The primary effector of cGMP signaling in Plasmodium is the cGMP-dependent protein kinase (PKG). Work in human-infective Plasmodium falciparum and rodent-infective Plasmodium berghei has provided biological validation of P. falciparum PKG (PfPKG) as a drug target for treating and/or protecting against malaria. PfPKG is essential in the asexual erythrocytic and sexual cycles as well as the pre-erythrocytic cycle. Medicinal chemistry efforts, both target-based and phenotype-based, have targeted PfPKG in the past few years. This review provides a brief overview of their results and challenges.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 03, 2021
- Source ID
- 10.3389/fmicb.2020.610408
Entities
People
- David P. Rotella
- John Siekierka
- Purnima Bhanot
Organizations
- National Institutes of Health
- United States Department of Defense